阿帕替尼治疗中晚期胃癌的疗效及预后影响因素分析

Efficacy of apatinib in treatment of advanced gastric cancer and the prognostic factors

目的分析阿帕替尼治疗中晚期胃癌的疗效,并探讨其预后影响因素。方法回顾性分析2018年1月至2019年1月本院收治的70例中晚期胃癌患者的临床资料。依据治疗方案的差异性,分为对照组(常规治疗,35例)与观察组(常规治疗+阿帕替尼,35例)。对照组男19例,女16例,年龄(67.43±5.19)岁,病程(2.38±0.84)年。观察组男20例,女15例,年龄(67.81±4.92)岁,病程(2.41±0.59)年。比较两组疗效,分析影响预后的因素。结果两组客观缓解率比较,差异无统计学意义(P>0.05);观察组疾病控制率高于对照组(42.86%比5.71%),差异有统计学意义(P<0.05);经logistic回归分析发现,年龄≥65岁、治疗时机(发病≥2年)、既往化疗二线以上、甲胎蛋白异常是影响胃癌患者预后的危险因素(均OR>1,均P<0.05)。结论阿帕替尼对中晚期胃癌疗效较好,可提高疾病控制率,对胃癌患者进行及早诊断与治疗,可通过改善患者甲胎蛋白异常,改善部分中晚期胃癌患者预后。

Objective To analyze the efficacy of apatinib in the treatment of advanced gastric cancer and to explore the prognostic factors.Methods The clinical data of 70 patients with advanced gastric cancer treated in our hospital from January,2018 to January,2019 were analyzed retrospectively.According to the different treatment schemes,they were divided into a control group,routinely treated,and an observation group,routinely treated and took aptinib,35 cases for each group.The curative effects of the two groups was compared.The factors affecting the prognosis were analyzed.Results There was no statistical difference in the objective remission rate between the two groups(P>0.05).The disease control rate in the observation group was higher than that in the control group(42.86%vs.5.71%;P<0.05).Logistic regression analysis showed that≥65 years old,treatment timing(onset≥2 years),previous chemotherapy of second line,and abnormal alpha-fetoprotein were the risk factors affecting the prognosis(all OR>1;all P<0.05).Conclusion Apatinib is effective in the treatment of advanced gastric cancer,and can improve the disease control rate.Early diagnosis and treatment of gastric cancer can improve the prognosis of some patients with advanced gastric cancer by improving the abnormal alphafetoprotein.